Under the [@b10-ehp-119-326], the U.S. Environmental Protection Agency (EPA) is legislatively required to establish and enforce National Ambient Air Quality Standards (NAAQS) that have a margin of safety requisite to protect the health of the public ([@b47-ehp-119-326]). In establishing the margin of safety for ambient particulate matter (PM) \< 2.5 μm (PM~2.5~) and \< 10 μm (PM~10~) in aerodynamic diameter, the U.S. EPA and the Clean Air Scientific Advisory Committee recently examined both innate (e.g., genetic or developmental) and acquired (e.g., disease- or treatment-related) forms of susceptibility to its adverse health effects, including increased risk of cardiovascular disease ([@b48-ehp-119-326]). Antihyperlipidemics and estrogens are noteworthy examples of the drug classes that were examined with treatment-related susceptibility to such effects in mind.

Several studies suggest that drugs in these classes modify the autonomic, atherosclerotic, and thrombotic effects of PM ([@b1-ehp-119-326]; [@b6-ehp-119-326]; [@b27-ehp-119-326]; [@b43-ehp-119-326]). In addition, in a case--control study set in northern Italy, [@b6-ehp-119-326] suggested that the association between PM and deep vein thrombosis is much weaker among women than among men, particularly among those women who were using hormone therapy. However, the existence of an interaction between PM and hormone therapy remains questionable because of the well-known potential for confounding associated with hormone therapy exposures in observational epidemiologic studies ([@b11-ehp-119-326]; [@b22-ehp-119-326]; [@b39-ehp-119-326]). At the same time, the relative risk and severity of adverse PM effects experienced by both hormone therapy users and nonusers remains important from the clinical, public health policy, and regulatory perspectives ([@b8-ehp-119-326], [@b9-ehp-119-326]), given the decreasing but otherwise pervasive use of hormone therapy among postmenopausal U.S. women ([@b24-ehp-119-326]; [@b46-ehp-119-326]). More information about a potential association between PM and venous thromboembolism (VTE) in a randomized controlled trial of hormone therapy is therefore needed.

In this study, we examined the association between PM and VTE and interaction between PM and hormone therapy in a randomized, placebo-controlled trial of estrogen (E) or estrogen plus progestin (E + P) among a large geographically and ethnically diverse population of postmenopausal women living in the United States.

Materials and Methods
=====================

Study population
----------------

The design of the Women's Health Initiative (WHI) Hormone Therapy trials has been described previously ([@b21-ehp-119-326]; [@b45-ehp-119-326]; [@b36-ehp-119-326]). Briefly, 27,347 postmenopausal women 50--79 years of age in areas surrounding 40 clinical centers were enrolled in one of two randomized, double-blind trials between 1993 and 1998. In the E trial, which was open only to women without a uterus, participants were randomized to either oral conjugated equine estrogen (CEE) 0.25 mg/day or placebo. In the E + P trial, women were randomized to CEE 0.625 mg/day plus oral medroxyprogesterone acetate 2.5 mg/day or placebo. Exclusion criteria differed slightly between the trials but were related to the presence of medical conditions associated with shortened survival or safety in both. Because of evidence of hormone therapy-related increases in VTE risk, women with a history of deep vein thrombosis or pulmonary embolism were no longer enrolled in either trial as of July 1997. The present study excluded 93 women who had no follow-up data, 312 women who reported a history of VTE at randomization, and 11 women who reported using anticoagulants or vitamin K. We also excluded 481 women with foreign addresses outside the United States, U.S. military, U.S. protectorate, Hawaiian, Alaskan, or missing addresses at the time of randomization or their event, all of which precluded estimation of PM exposures; a total of 26,450 women were included in the PM~10~ analyses. Analyses of PM~2.5~ excluded another 124 women who had a VTE event and 1,693 who dropped out of the trials before 1999, because PM~2.5~ data before 1999 were unavailable (see "Environmental exposures"). The recruitment, consent, and data collection processes of the study are overseen by institutional review boards at the Clinical Coordinating Center in the Fred Hutchinson Cancer Research Center and the 40 WHI clinical centers. All participants provided written informed consent.

VTE event ascertainment
-----------------------

Study participants were followed up to assess clinical events every 6 months and for an annual in-clinic visit ([@b13-ehp-119-326]; [@b14-ehp-119-326]). All hospital records associated with possible VTE events were locally reviewed by trained physician adjudicators who were masked to treatment assignment and then centrally adjudicated. A VTE event was defined as a centrally adjudicated deep vein thrombosis or pulmonary embolism that occurred between the date of randomization and 31 December 2004 ([@b13-ehp-119-326]); our primary outcome was the calendar date of the first VTE event postrandomization. Agreement between local and central adjudication was 97% ([@b13-ehp-119-326]). A diagnosis of deep vein thrombosis required documentation of a treating physician's diagnosis and positive results of Doppler or duplex ultrasonography, venography, plethysmography, or isotope scanning. A pulmonary embolism required documentation of a physician's diagnosis and by positive results from ventilation-perfusion lung scanning, pulmonary angiography, or computed tomography or by documented signs and symptoms suggestive of pulmonary embolism in the presence of a documented deep vein thrombosis event. Both procedure-related (defined as events that occurred within 60 days after an invasive procedure) and nonprocedure-related events were included in the definition of VTE events for this study ([@b13-ehp-119-326]; [@b14-ehp-119-326]).

Environmental exposures
-----------------------

We used data on the ambient concentrations of PM recorded at all U.S. EPA Air Quality System monitors operating in the contiguous United States and national-scale, log-normal ordinary kriging to spatially interpolate daily mean PM concentrations at each geocoded participant address during the study period ([@b29-ehp-119-326]; [@b52-ehp-119-326]). Women were assigned time-varying PM measures for all calendar dates on which a VTE event occurred. Monitor data were available for PM~10~ and PM~2.5~ between 1993--2004 and 1999--2004, respectively. We averaged spatially interpolated daily means over 1, 7, 30, and 365 days up to and including the event date among women with VTE and among women who remained at risk at that date. Averaging times were left-truncated for the cohort because of the lack of PM data before randomization. Thus, the 7-day, 30-day, and 365-day average concentrations associated with events that occured less than 7, 30, and 365 days after the randomization date were not calculable. We computed corresponding averaging times for daily mean temperature (degrees centigrade) using ambient temperature data recorded at all National Climatic Data Center meteorological stations within 50 km of each geocoded address of the participants.

Participant and neighborhood characteristics
--------------------------------------------

We examined the following participant characteristics as possible confounders of the association between PM and VTE: age (years); race/ethnicity (non-Hispanic black, non-Hispanic white, Hispanic, and other); education (four categories); history of coronary heart disease, peripheral arterial disease, or stroke; any cancer excluding nonmelanomatous skin cancers; femur or hip fracture; hypercholesterolemia; use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs); current smoking; body mass index (BMI; kilograms per meter squared); and physical activity (kilocalories per week per kilogram). Self-reported education, medication use over the previous 2 weeks, medical history, and other characteristics were determined at each visit by interview and examination by trained and certified staff. Interim health events were identified via standardized medical record review and physician adjudication. Hypercholesterolemia was determined by history or use of antihyperlipidemics; peripheral arterial disease and coronary heart disease were determined by self-reported history at baseline or by medication use and incident disease during the follow-up period that was assessed through a review of medical records by trained adjudicators. We also examined a measure of census tract--level neighborhood socioeconomic status (SES) because of its inverse association with other cardiovascular outcomes in this population ([@b7-ehp-119-326]). To construct neighborhood SES values we identified 12 theoretically relevant census-tract level variables from census data, and assessed their relationships using confirmatory factor analysis ([@b7-ehp-119-326]). We created an index from the six variables that loaded most highly on the factor that most represented SES: percentage of adults older than age 25 years with less than a high school education; percentage of unemployed men; percentage of households with income below the poverty line; percentage of households receiving public assistance; percentage of households with children headed only by a female; and the median household income. We imputed missing values of baseline individual-level covariates using Imputation and Variance Estimation Software (IVEware; [@b38-ehp-119-326]). All of the covariates listed above, except race/ethnicity and education, were time-varying covariates with values being updated on the calendar-time scale.

Statistical analysis
--------------------

Cox proportional hazard models analyzed time until VTE event, controlling for clustering within clinical centers. As detailed below, all models used calendar time as the time scale to minimize potential biases associated with comparing VTE risk at a given event date as a function of PM concentration. Thus, we considered the following model:
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where λ~0~*~j~*(*t*) denotes the baseline hazard for the *j*th strata, *t* denotes calendar time, *PM*(*t*) denotes an individual's PM value at time *t*, and *X*(*t*) and *X* denote the vectors containing the time-varying and time-invariant covariates used as controls in the model, respectively. We note that this model structure assumes that the effect of PM is acute, as only the value of PM at time *t* is allowed to impact risk of VTE for an individual ([@b20-ehp-119-326]; [@b26-ehp-119-326]). Separate analyses were conducted for PM~10~ and PM~2.5~.

We used unadjusted models to examine the bivariate relationship between PM and VTE. Fully adjusted models controlled for trial membership (E vs. E + P), a within-trial indicator for treatment arm (active vs. placebo), time on study (days), continuous temperature (degrees centigrade), as well as the participant and neighborhood characteristics that we defined previously. Within each model, the averaging times for PM and temperature were identical. We used SAS (version 9.1.3; SAS Institute Inc., Cary, NC) to fit all models and inspected weighted Schoenfeld residual plots to test the assumption of proportional hazards for all covariates ([@b19-ehp-119-326]). Because of nonproportionality, all models were stratified by birth cohort in 5-year increments and by trial membership. All nondemographic variables were allowed to vary over the course of follow-up except for neighborhood SES and physical activity, which were measured at baseline.

All analyses began by combining data from the E and E + P trials with an indicator for active treatment in either trial. Combined trial analyses were followed by separate analyses of the E and E + P trial data. In each analysis, we first assessed the PM main effect using separate models for the 1-day, 7-day, 30-day, and 365-day average PM~10~ and PM~2.5~ concentrations and then the interactive effect between PM and treatment arm for each PM concentration. We assessed the interaction between PM and treatment arm by examining the addition of a linear PM × hormone therapy treatment arm interaction term and by comparing stratified models (E alone, E placebo, E + P, and E + P placebo) to assess nonlinear interaction effects. PM-covariate interaction terms were also examined. Statistical significance was determined using a *p*-value of 0.05.

Time scale selection
--------------------

The survival models presented above rely on a calendar time scale instead of time on study (time since randomization). When combined with time-varying PM exposure measures, the calendar time scale allows for more robust inferences concerning the association between PM and VTE. In particular, we normalized the events to the calendar time scale and computed time-varying measures of PM by time-averaging the PM data of each woman at risk of VTE for each of the actual VTE event dates. This method minimizes confounding by season and long-term trends commonly found in PM data analyses; provides a more meaningful summary of exposures of women who never experienced a VTE event (compared with simply allowing their PM exposures at loss to follow-up to represent their PM exposures over the entire follow-up period); and more appropriately models the effects of PM on VTE as short term or acute in nature.

Results
=======

Characteristics of the population
---------------------------------

Of the 26,450 women without a baseline history of VTE who met the inclusion criteria, 508 (2.0%, or 2.6/1,000 person-years) had a VTE event: 202 (2.0%, or 2.6/1,000 person-years) in the E trial (mean follow-up, 7.5 years) and 306 (1.9%, or 2.5/1,000 person-years) in the E + P trial (mean follow-up, 7.6 years). Women who experienced a VTE event during the follow-up period tended to be older and non-Hispanic white, to have had a history of stroke or cancer, to have been taking aspirin or an NSAID, and to have been randomly assigned to estrogen, with or without progestin, at baseline compared with women who did not have a VTE event during follow-up ([Table 1](#t1-ehp-119-326){ref-type="table"}). In [Table 2](#t2-ehp-119-326){ref-type="table"} we present the mean PM concentrations for each averaging period for the overall sample and by trial arm and VTE status.

Associations between PM and VTE and interactions between PM and hormone therapy treatment arm
---------------------------------------------------------------------------------------------

Fully adjusted models that included baseline neighborhood SES data for neighborhoods were similar to those without neighborhood SES. Neighborhood SES was not significantly associated with VTE and therefore was not included in the fully adjusted models reported herein. In the combined trial analyses, unadjusted and adjusted overall hazard ratios (HRs) for VTE per 10-μg/m^3^ increase in PM~2.5~ and in PM~10~ were close to and not significantly different from 1.0, regardless of the PM averaging period ([Table 3](#t3-ehp-119-326){ref-type="table"}). HRs and 95% confidence intervals (CIs) for VTE associated with other model covariates in the combined trial analyses for PM~10~ are shown in Supplemental Material, Table A (doi:10.1289/ehp.1002256). Overall HRs in the trial-stratified analyses also were no different from the null, although they were somewhat higher among women in the E + P than in the E trial, except for the 30-day PM~2.5~ average ([Table 4](#t4-ehp-119-326){ref-type="table"}). The interaction terms between PM and randomized hormone therapy within each trial were not statistically significant (*p* \> 0.05), regardless of the PM-averaging period ([Table 4](#t4-ehp-119-326){ref-type="table"}). Moreover, *p*-values associated with other PM-covariate interactions exceeded 0.1 (results not shown).

Sensitivity analyses
--------------------

In addition to the primary analyses, we evaluated the sensitivity of findings to alternative exposure metrics, outcome definitions, time scales, analytic methods, and trial-specific censoring dates. For example, we dichotomized 1-day and 365-day average PM concentrations at values representing current U.S. EPA regulatory standards to evaluate potential threshold effects of exposure ([@b49-ehp-119-326]). We also examined restricted distributed lag models ([@b37-ehp-119-326]; [@b42-ehp-119-326]) to evaluate PM effects as a cubic function of lagged daily concentrations within the 7-day averaging period. In addition to the primary VTE outcome, pulmonary embolism (without coincident deep vein thrombosis) and deep vein thrombosis (without coincident pulmonary embolism) were also examined to evaluate their individual associations with PM and interactions between PM and hormone therapy. In other analyses, time on study was substituted for calendar time to evaluate whether use of the calendar time scale masked the true effect of PM ([@b35-ehp-119-326]). Moreover, although in the primary analyses the censoring date was 31 December 2004, the last date for which PM data were available, we examined whether associations using this date were different from those using the end dates of the two hormone therapy trials (8 July 2002 for the E trial; 1 March 2004 for the E + P trial) by restricting the follow-up time to events that occurred before those dates for each trial and rerunning all combined and trial-stratified models. Finally, we applied a case-crossover design using conditional logistic regression to analyze the odds of VTE in case compared with bidirectionally sampled case--referent exposure periods. These models controlled for short-term time trends in PM exposure and adjusted for average ambient temperature. All findings were robust to the adoption of the alternative exposure metrics, outcome definitions, time scales, analytic methods, and trial-specific censoring dates (see "Materials and Methods"). In the adjusted analyses of the 365-day average PM~2.5~ and PM~10~ on the time on study scale, for example, the combined trial HRs were consistently null: 0.88 (95% CI, 0.52--1.47) and 1.10 (95% CI, 0.75--1.61), respectively, as were the trial-stratified HRs. In the case-crossover analyses, odds ratios (95% CIs) for VTE per 10-μg/m^3^ increase in average 1-day and 7-day PM~2.5~ were 1.04 (0.85--1.28) and 0.93 (0.68--1.27), respectively. The odds ratios for a 10-μg/m^3^ increase in 1-day and 7-day PM~10~, were 1.03 (0.92--1.14) and 0.99 (0.81--1.20), respectively.

Discussion
==========

In this large clinical trial population, we observed little evidence for an association of either PM~10~ or PM~2.5~ air pollution with risk of future VTE, over more than 7 years of follow-up. Results were robustly null in analyses that examined daily, weekly, monthly, and annual average PM concentrations immediately preceding VTE events, adjusting for a comprehensive set of sociodemographic, clinical, behavioral, and environmental covariates. There were no differences in findings comparing women who were randomized to placebo or hormone therapy.

Although the current study did not find any consistent evidence of a direct association between VTE risk and short-term or long-term PM~2.5~ or PM~10~ exposures in primary or sensitivity analyses, [@b6-ehp-119-326] found a strong, direct, and significant association between PM~10~ exposure and the risk of deep vein thrombosis in a case--control study conducted in the Lombardy region of Italy. This finding was internally consistent with the PM-related decreases in prothrombin time and in activated partial thromboplastin time that the study also observed among its controls. Moreover, other studies have suggested links between traffic or PM~10~ exposure, deep vein thrombosis ([@b5-ehp-119-326]), pulmonary embolism ([@b12-ehp-119-326]), and VTE ([@b15-ehp-119-326]). The discrepant findings may be partly attributable to differences between study populations; for example, [@b6-ehp-119-326] included both men and women in their study. They observed lower VTE risk among women than among men, suggesting that there could be inherent or acquired differences in risk for VTE by sex that we were not able to observe in our sample of women. Women in the WHI Hormone Therapy trials were also older than those reported in [@b6-ehp-119-326], uniformly postmenopausal, mostly well educated, and likely to have had a substantial interest in their health. In addition, the association between PM~10~ and deep vein thrombosis described by [@b6-ehp-119-326] was not adjusted for history of cancer, which is a risk factor for deep vein thrombosis ([@b2-ehp-119-326]; [@b18-ehp-119-326]; [@b31-ehp-119-326]; [@b44-ehp-119-326]). Finally, the chemical composition of ambient PM and its correlation with personal PM exposures may differ in northern Italy and in the United States ([@b16-ehp-119-326]; [@b17-ehp-119-326]; [@b30-ehp-119-326]).

Although PM-chemical component data are currently unavailable in the WHI, we were able to examine hormone therapy-related susceptibility to the putative effects of PM on VTE risk in the context of a randomized clinical trial of estrogen with or without progestin. We did not find a consistent clinically or statistically significant interactive effect of hormone therapy. [@b6-ehp-119-326] also examined the interactive effects of PM and exogenous estrogens on risk of deep vein thrombosis with or without pulmonary embolism; although no significant interactions were found at a Bonferroni-corrected alpha of 0.004, the strong and direct association between PM and deep vein thrombosis described by the researchers was much weaker among women than among men and among users of oral contraceptives or hormone therapy compared with women who were nonusers. These findings were counterintuitive, because the prothrombotic effects of PM ([@b28-ehp-119-326]) and estrogen ([@b13-ehp-119-326]; [@b14-ehp-119-326]; [@b23-ehp-119-326]; [@b41-ehp-119-326]) were expected to be synergistic ([@b8-ehp-119-326]). However, the case--control design of the study did not benefit from the equalization among treatment groups of measured, and most important, unmeasured confounders that randomization typically affords. Studies that report protective effects of hormone therapy against coronary heart disease in observational settings conflict with more recent randomized trials of hormone therapy ([@b13-ehp-119-326]) and with reanalyses of those observational associations using methods less prone to bias ([@b11-ehp-119-326]; [@b22-ehp-119-326]; [@b39-ehp-119-326]). Thus, the putative effects of hormone therapy and its interactive effects with PM on VTE are particularly important to examine in the context of a randomized trial, as has been done here, although neither PM exposure nor its interaction with hormone therapy was randomized.

Prior findings from the WHI Observational Study are useful in placing the present findings from the WHI Hormone Therapy trials into proper perspective. Those findings included a 24% (95% CI, 9--41) increase in the risk of a cardiovascular event, including death from coronary heart disease, or cerebrovascular disease, coronary revascularization, myocardial infarction, and stroke per 10-μg/m^3^ increase in the annual average PM~2.5~ concentration ([@b33-ehp-119-326]). The strength of that effect also varied in a striking and consistent way with several anthropometric measures. The generally null main and interactive effects described here contrast sharply with those of [@b33-ehp-119-326] and suggest that observations of the WHI populations pertaining to the atherosclerotic and arterial effects of PM~2.5~ do not necessarily apply to its thromboembolic and venous effects, as has been intimated previously ([@b8-ehp-119-326], [@b9-ehp-119-326]).

The strengths of this study include the examination of a geographically and demographically diverse population of U.S. women who participated in a large randomized trial of postmenopausal hormone therapy, the rigor with which VTE outcomes were ascertained, and the analysis of PM~10~ as well as PM~2.5~, the particle size most relevant to regulatory efforts in the United States. Moreover, we distinguished between the effects of short-term (1-day or 7-day), medium-term (30-day), and long-term (365-day) exposures to both PM~2.5~ and PM~10~ on both pulmonary embolism and deep vein thrombosis risk, using previously validated PM exposures measured across 1,270 counties in the United States ([@b29-ehp-119-326]).

Despite these strengths, we note several limitations. First, this study is based on postmenopausal women 50--79 years of age who lived in the contiguous United States between 1993 (or 1999 for those with PM~2.5~ measures) and 2004. Thus, inferences may not be generalizable to the U.S. population of adults including men and premenopausal women. Second, the distribution of PM concentrations in this study may not be fully representative of individual PM exposures across the United States. The temporally and spatially heterogeneous PM concentrations in this study are nonetheless associated with means, variances, and ranges comparable with those recorded by the U.S. EPA over the same time frame ([@b50-ehp-119-326]). Third, ambient PM concentrations estimated in this study may not adequately represent total PM exposures ([@b3-ehp-119-326], [@b4-ehp-119-326]) as participants may have been exposed to occupational or indoor PM with physicochemical properties and toxicities that differ from those of ambient PM ([@b34-ehp-119-326]; [@b51-ehp-119-326]). Even so, surveys of human-activity patterns suggest that individuals spend a majority of their time at home ([@b25-ehp-119-326]), the location where ambient PM concentrations in this study were estimated.

Conclusions
===========

We consistently found little evidence of an association between VTE and PM~2.5~ or PM~10~ concentrations in this study. Although innate participant characteristics remain unaccounted for in this study---including those that may influence genetic susceptibility to PM effects on VTE ([@b13-ehp-119-326]; [@b14-ehp-119-326]; [@b23-ehp-119-326]; [@b32-ehp-119-326]; [@b40-ehp-119-326])---genome-wide association studies (GWAS) are beginning to offer new opportunities to examine gene-PM interactions. Such studies hold promise for improved understanding of genetic and environmental susceptibility to VTE.

Supplemental Material is available online (doi: 10.1289/ehp.1002256 via <http://dx.doi.org/>).
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###### 

Baseline characteristics, overall and by VTE status.

                                                        VTE status                      
  ----------------------------------------------------- --------------- --------------- ------------
  Age (years)                                           63.4 ± 7.2      63.4 ± 7.2      66.1 ± 6.6
  Race/ethnicity                                                                        
   Non-Hispanic white                                   21,609 (81.7)   21,166 (81.6)   443 (87.2)
   Non-Hispanic black                                   2,699 (10.2)    2,646 (10.2)    53 (10.4)
   Hispanic                                             1,498 (5.7)     1,491 (5.7)     7 (1.4)
   Other                                                644 (2.4)       639 (2.5)       5 (1.0)
  Education                                                                             
   Some high school                                     2,130 (8.0)     2,085 (8.0)     45 (8.9)
   High school graduate                                 5,454 (20.6)    5,348 (20.6)    106 (20.9)
   Some college                                         10,733 (40.6)   10,531 (40.6)   202 (39.7)
   ≥ College degree                                     8,133 (30.8)    7,978 (30.8)    155 (30.5)
  BMI (kg/m^2^)                                         29.1 ± 6.0      29.1 ± 6.0      31.2 ± 6.6
  Coronary heart disease                                494 (1.9)       484 (1.9)       10 (2.0)
  Peripheral arterial disease                           440 (1.7)       429 (1.7)       11 (2.2)
  Stroke                                                294 (1.1)       285 (1.1)       9 (1.8)
  Hypercholesterolemia                                  3,206 (12.1)    3,146 (12.1)    60 (11.8)
  Cancer                                                840 (3.2)       817 (3.1)       23 (4.5)
  Fracture[a](#tfn2-ehp-119-326){ref-type="table-fn"}   211 (0.8)       206 (0.8)       5 (1.0)
  Aspirin or NSAID use                                  10,150 (38.4)   9,906 (38.2)    244 (48.0)
  Current smoking                                       2,735 (10.5)    2,693 (10.5)    50 (8.4)
  Physical activity (kcal/kg/week)                      10.0 ± 11.2     10.0 ± 11.2     8.7 ± 10.6
  Randomization status                                                                  
   E                                                    5,104 (19.3)    4,991 (19.2)    113 (22.2)
   Placebo for E arm                                    5,228 (19.8)    5,139 (19.8)    89 (17.5)
   E + P                                                8,255 (31.2)    8,064 (31.1)    191 (37.6)
   Placebo for E + P arm                                7,863 (29.7)    7,748 (29.9)    115 (22.6)
  Daily temperature (°C)                                NA              NA              13.0 ± 9.5
  Season                                                                                
   January--March                                       NA              NA              177 (34.8)
   April--June                                          NA              NA              124 (24.4)
   July--September                                      NA              NA              150 (29.5)
   October--December                                    NA              NA              57 (11.2)
  Follow-up time (person-years)                         198,048         195,898         2,150

Abbreviations: E, CEE, 0.625 mg/day; E + P, CEE, 0.625 mg/day plus medroxyprogesterone acetate, 0.25 mg/day; NA, not applicable for participants without event. Data are reported as *n* (%) or mean ± SD. Descriptive data include imputed baseline covariate data.

Hip or femur.

###### 

Overall mean ± SD PM concentrations at baseline, by trial arm and by VTE status.

                                    E trial       E + P trial                                                                        
  ------------------- ------------- ------------- ------------- ------------- ------------ ------------- ------------- ------------- -------------
  PM~2.5~ (μg/m^3^)                                                                                                                  
                                                                                                                                     
   1                  13.5 ± 7.7    13.5 ± 7.7    12.5 ± 7.2    13.5 ± 7.7    12.9 ± 7.0   13.5 ± 7.8    13.0 ± 7.3    13.5 ± 7.7    15.3 ± 9.3
   7                  13.5 ± 5.6    13.5 ± 5.6    12.5 ± 6.1    13.5 ± 5.6    13.7 ± 5.1   13.5 ± 5.6    13.7 ± 5.9    13.5 ± 5.6    13.6 ± 5.8
   30                 13.4 ± 4.4    13.4 ± 4.4    12.9 ± 4.1    13.4 ± 4.4    13.6 ± 4.1   13.4 ± 4.4    13.7 ± 4.3    13.4 ± 4.4    13.6 ± 4.8
   365                13.4 ± 2.9    13.4 ± 2.9    13.1 ± 2.5    13.4 ± 2.9    13.2 ± 2.8   13.3 ± 2.8    13.7 ± 2.4    13.4 ± 2.8    13.4 ± 2.9
                                                                                                                                     
  PM~10~ (μg/m^3^)                                                                                                                   
                                                                                                                                     
   1                  27.8 ± 12.3   27.9 ± 12.3   28.1 ± 10.9   27.9 ± 12.2   25.6 ± 9.6   27.7 ± 12.2   26.7 ± 10.3   27.7 ± 12.3   27.5 ± 12.0
   7                  27.1 ± 8.0    27.2 ± 8.0    26.0 ± 7.7    27.2 ± 8.0    26.4 ± 7.3   27.0 ± 7.9    26.8 ± 8.0    27.0 ± 8.0    26.5 ± 7.6
   30                 26.7 ± 6.1    26.8 ± 6.2    26.4 ± 6.2    26.9 ± 6.2    25.8 ± 5.3   26.7 ± 6.1    26.6 ± 6.2    26.7 ± 6.1    26.4 ± 6.0
   365                26.7 ± 3.6    26.8 ± 3.7    26.7 ± 3.7    26.8 ± 3.7    26.7 ± 3.3   26.6 ± 3.6    26.8 ± 3.4    26.6 ± 3.6    26.7 ± 3.4

Periods (up to and ending on VTE event dates) over which averages were calculated. For those without VTE, averages are the corresponding averages over all at-risk days.

###### 

HRs (95% CIs) for VTE per 10-μg/m^3^ increase in PM.[a](#tfn4-ehp-119-326){ref-type="table-fn"}

  Averaging period (days)   Unadjusted HR (95% CI)   Adjusted HR (95% CI)
  ------------------------- ------------------------ ----------------------
  PM~2.5~                                            
                                                     
   1                        1.01 (0.88--1.16)        1.04 (0.89--1.22)
   7                        0.97 (0.78--1.20)        1.00 (0.78--1.28)
   30                       0.99 (0.76--1.29)        1.02 (0.73--1.43)
   365                      1.03 (0.66--1.62)        0.93 (0.54--1.60)
                                                     
  PM~10~                                             
                                                     
   1                        0.94 (0.86--1.03)        0.98 (0.88--1.10)
   7                        0.88 (0.76--1.02)        0.91 (0.77--1.08)
   30                       0.87 (0.71--1.05)        0.93 (0.74--1.16)
   365                      0.92 (0.65--1.29)        1.05 (0.72--1.53)

Models were stratified by birth cohort (in 5-year increments) and trial arm. Adjusted models include race/ethnicity, education, BMI, coronary heart disease, peripheral arterial disease, stroke, cancer, fracture, aspirin or NSAID use, hypercholesterolemia, current smoking, physical activity, hormone therapy treatment arm (active vs. placebo), treatment duration (years), and temperature (degrees centigrade).

###### 

HRs (95% CIs) for VTE per 10-μg/m^3^ increase in PM, by randomization status.[a](#tfn5-ehp-119-326){ref-type="table-fn"}

            E trial             E + P trial                                                                                                
  --------- ------------------- ------------------- ------------------- ------ ------------------- ------------------- ------------------- ------
  PM~2.5~                                                                                                                                  
                                                                                                                                           
   1        0.97 (0.79--1.18)   0.94 (0.68--1.31)   0.98 (0.74--1.31)   0.86   1.10 (0.87--1.4)    0.97 (0.67--1.41)   1.18 (0.88--1.60)   0.42
   7        0.98 (0.70--1.37)   0.78 (0.40 1.53)    1.13 (0.81--1.58)   0.32   1.01 (0.75--1.36)   1.12 (0.69--1.81)   0.94 (0.63--1.41)   0.60
   30       1.07 (0.66--1.75)   0.76 (0.36--1.63)   1.31 (0.81--2.13)   0.14   0.98 (0.65--1.47)   1.02 (0.50--2.1)    0.95 (0.58--1.55)   0.86
   365      0.67 (0.34--1.29)   0.54 (0.21--1.38)   0.77 (0.32--1.84)   0.58   1.21 (0.57--2.56)   2.07 (0.77--5.61)   0.81 (0.31--2.07)   0.12
                                                                                                                                           
  PM~10~                                                                                                                                   
                                                                                                                                           
   1        0.95 (0.84--1.09)   1.06 (0.93--1.22)   0.87 (0.71--1.05)   0.06   1.01 (0.86--1.18)   0.97 (0.79--1.2)    1.02 (0.86--1.22)   0.67
   7        0.90 (0.70--1.15)   0.86 (0.60--1.24)   0.93 (0.68--1.26)   0.74   0.92 (0.75--1.13)   0.95 (0.70--1.28)   0.90 (0.72--1.13)   0.78
   30       0.89 (0.64--1.24)   1.02 (0.65--1.59)   0.82 (0.55--1.21)   0.41   0.96 (0.72--1.29)   1.00 (0.62--1.61)   0.94 (0.70--1.26)   0.79
   365      0.83 (0.50--1.38)   1.04 (0.39--2.75)   0.71 (0.41--1.24)   0.52   1.23 (0.78--1.93)   1.29 (0.65--2.53)   1.20 (0.75--1.91)   0.83

Models were stratified by birth cohort and trial arm and adjusted for race/ethnicity, education, BMI, coronary heart disease, peripheral arterial disease, stroke, cancer, fracture, aspirin or NSAID use, hypercholesterolemia, current smoking, physical activity, treatment duration (years), and temperature (degrees centigrade).

*p*-Value for the test of the PM × treatment interaction.

[^1]: R.A.S., B.A.G., A.J., C.E., and C.E.B. are employed by the RAND Corporation. The authors declare they have no actual or potential competing financial interests.
